SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Zosano Pharma Corporation (ZSAN) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 34/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ZSAN
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio79.60
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.27
Book Value / Share$0.00
Revenue / Share$0.01
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$6.98 |
$11.62M |
$1.82M |
15.6% |
| 2013 |
$-21.52 |
$4.25M |
$-5.61M |
-132% |
| 2014 |
$-24.52 |
$2.86M |
$-14.24M |
-497.8% |
| 2015 |
$-49.81 |
$313K |
$-28.43M |
-9082.1% |
| 2016 |
$-43.32 |
$0.00 |
$-29.83M |
- |
| 2017 |
$-16.82 |
$0.00 |
$-29.11M |
- |
| 2018 |
$-3.74 |
$0.00 |
$-35.36M |
- |
| 2019 |
$-2.29 |
$0.00 |
$-37.59M |
- |
| 2020 |
$-0.49 |
$224K |
$-33.37M |
-14896.9% |
| 2021 |
$-0.27 |
$785K |
$-30.11M |
-3836.2% |
